Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRd salvage plus autologous stem cell transplant for newly diagnosed multiple myeloma with suboptimal response to bortezomib
ACTRN12618001490268Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, lenalidomide, dexamethasone, melphalan and filgrastim in multiple myeloma (MM), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Overall response rate after DRd salvage. Started Mar 2019; status: completed.
02
Drugs
daratumumablenalidomidedexamethasonemelphalanfilgrastim
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12618001490268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001490268.